Keep Big Picture In Focus, Have Clarity On Specifics Responding To GMP Violations
Executive Summary
Avoid “absolute chaos” and last-minute changes as well as over-reaction responding to FDA officials’ form 483s listing GMP violations found during inspections, says Teresa Gorecki, practice director at Compliance Architects.
You may also be interested in...
US FDA Targets Expanding Conduit For Supplement GMP Compliance Information
Gathering GMP information can be as problematic for agency as keeping tabs on all supplements available to US consumers. “Just to be clear, FDA believes we have a data gap in understanding the extent of the dietary supplements in the marketplace,” says ODSP Director Cara Welch.
Supplement GMP Warnings Followed After US FDA Restarted Facility Inspections
GMP warnings to firms making supplement firms marketed in US have been rare since FDA temporarily suspended on-site inspections with onset of COVID-19 pandemic. But GMP problems surfaced after agency resumed inspections last July.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.